Tempus AI, Inc. (TEM)
TEM Stock Price Chart
Explore Tempus AI, Inc. interactive price chart. Choose custom timeframes to analyze TEM price movements and trends.
TEM Company Profile
Discover essential business fundamentals and corporate details for Tempus AI, Inc. (TEM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Healthcare Information Services
IPO Date
14 Jun 2024
Employees
3.80k
Website
https://www.tempus.comCEO
Eric Lefkofsky
Description
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
TEM Financial Timeline
Browse a chronological timeline of Tempus AI, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is -$0.13, while revenue estimate is $379.54m.
Earnings released on 5 May 2026
EPS came in at -$0.13 surpassing the estimated -$0.21 by +38.10%, while revenue for the quarter reached $348.12m , beating expectations by +0.77%.
Earnings released on 24 Feb 2026
EPS came in at -$0.04 surpassing the estimated -$0.04 by +8.76%, while revenue for the quarter reached $367.21m , beating expectations by +1.29%.
Earnings released on 4 Nov 2025
EPS came in at -$0.11 surpassing the estimated -$0.17 by +36.15%, while revenue for the quarter reached $334.21m , beating expectations by +1.67%.
Earnings released on 8 Aug 2025
EPS came in at -$0.22 surpassing the estimated -$0.23 by +4.30%, while revenue for the quarter reached $314.64m , beating expectations by +5.67%.
Earnings released on 6 May 2025
EPS came in at -$0.24 surpassing the estimated -$0.26 by +7.70%, while revenue for the quarter reached $255.74m , beating expectations by +3.07%.
Earnings released on 24 Feb 2025
EPS came in at -$0.18 falling short of the estimated -$0.15 by -20.00%, while revenue for the quarter reached $200.68m , missing expectations by -19.36%.
Earnings released on 4 Nov 2024
EPS came in at -$0.25 surpassing the estimated -$0.27 by +6.04%, while revenue for the quarter reached $180.93m , beating expectations by +0.78%.
Earnings released on 6 Aug 2024
EPS came in at -$0.63 falling short of the estimated -$0.59 by -6.78%, while revenue for the quarter reached $165.97m , missing expectations by -7.55%.
Earnings released on 17 Jun 2024
EPS came in at -$0.38 , while revenue for the quarter reached $145.82m .
Earnings released on 31 Dec 2023
EPS came in at -$0.30 , while revenue for the quarter reached $147.72m .
Earnings released on 30 Sept 2023
EPS came in at -$0.31 , while revenue for the quarter reached $136.06m .
Earnings released on 30 Jun 2023
EPS came in at -$0.33 , while revenue for the quarter reached $132.42m .
Earnings released on 31 Mar 2023
EPS came in at -$0.32 , while revenue for the quarter reached $115.62m .
Earnings released on 31 Dec 2022
EPS came in at -$0.39 , while revenue for the quarter reached $100.63m .
Earnings released on 30 Dec 2021
EPS came in at -$0.35 , while revenue for the quarter reached $73.31m .
Earnings released on 29 Sept 2021
EPS came in at -$0.40 , while revenue for the quarter reached $52.45m .
TEM Stock Performance
Access detailed TEM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
